{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:22:15Z","timestamp":1787026935335,"version":"build-2736575974"},"reference-count":130,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007208","name":"Vanderbilt-Ingram Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007208","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Gastrointestinal (GI) cancers that include all cancers of the digestive tract organs are generally associated with obesity, lack of exercising, smoking, poor diet, and heavy alcohol consumption. Treatment of GI cancers typically involves surgery followed by chemotherapy and\/or radiation. Unfortunately, intrinsic or acquired resistance to these therapies underscore the need for more effective targeted therapies that have been proven in other malignancies. The aggressive features of GI cancers share distinct signaling pathways that are connected to each other by the overexpression and activation of AXL receptor tyrosine kinase. Several preclinical and clinical studies involving anti-AXL antibodies and small molecule AXL kinase inhibitors to test their efficacy in solid tumors, including GI cancers, have been recently carried out. Therefore, AXL may be a promising therapeutic target for overcoming the shortcomings of standard therapies in GI cancers.<\/jats:p>","DOI":"10.3389\/fonc.2023.1079041","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T12:45:44Z","timestamp":1688474744000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Altered expression of AXL receptor tyrosine kinase in gastrointestinal cancers: a promising therapeutic target"],"prefix":"10.3389","volume":"13","author":[{"given":"Nataliya","family":"Pidkovka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbes","family":"Belkhiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","unstructured":"WHOGlobal health estimates 2020: deaths by cause, age, sex, by country and by region 2000-20192020"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0993","article-title":"Multiple roles for the receptor tyrosine kinase axl in tumor formation","volume":"65","author":"Holland","year":"2005","journal-title":"Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2997","article-title":"R428, a selective small molecule inhibitor of axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer","volume":"70","author":"Holland","year":"2010","journal-title":"Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18468","article-title":"Phospho-AXL is widely expressed in glioblastoma and associated with significant shorter overall survival","volume":"8","author":"Onken","year":"2017","journal-title":"Oncotarget"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1404848111","article-title":"Direct regulation of GAS6\/AXL signaling by HIF promotes renal metastasis through SRC and MET","volume":"111","author":"Rankin","year":"2014","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26882","article-title":"Axl signaling is an important mediator of tumor angiogenesis","volume":"10","author":"Tanaka","year":"2019","journal-title":"Oncotarget"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3390\/cancers12071850","article-title":"Gas6\/Axl signaling pathway in the tumor immune microenvironment","volume":"12","author":"Tanaka","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2020.07.010","article-title":"AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer","volume":"138","author":"Cardone","year":"2020","journal-title":"Eur J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S257606","article-title":"Implications of the receptor tyrosine kinase axl in gastric cancer progression","volume":"13","author":"He","year":"2020","journal-title":"Onco Targets Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.10.10.13248","article-title":"The axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma","volume":"10","author":"Hector","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-020-01066-4","article-title":"Inhibiting the GAS6\/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma","volume":"23","author":"Bae","year":"2020","journal-title":"Gastric Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25483","article-title":"Overexpression of receptor tyrosine kinase axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma","volume":"117","author":"Song","year":"2011","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e47052","DOI":"10.15252\/embr.201847052","article-title":"The novel lncRNA CALIC upregulates AXL to promote colon cancer metastasis","volume":"20","author":"Kawasaki","year":"2019","journal-title":"EMBO Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1158\/0008-5472.CAN-20-2066","article-title":"Axl and mertk receptors cooperate to promote breast cancer progression by combined oncogenic signaling and evasion of host antitumor immunity","volume":"81","author":"Davra","year":"2021","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.10.034","article-title":"TAM receptors are pleiotropic inhibitors of the innate immune response","volume":"131","author":"Rothlin","year":"2007","journal-title":"Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12395","article-title":"Transcriptional upregulation of c-MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma","volume":"12","author":"Hong","year":"2018","journal-title":"Mol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-3151","article-title":"ABL regulation by AXL promotes cisplatin resistance in esophageal cancer","volume":"73","author":"Hong","year":"2013","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/0378-1119(93)90109-G","article-title":"The human TYRO3 gene and pseudogene are located in chromosome 15q14-q25","volume":"134","author":"Polvi","year":"1993","journal-title":"Gene"},{"key":"B20","article-title":"A novel putative tyrosine kinase receptor with oncogenic potential","volume":"6","author":"Janssen","year":"1991","journal-title":"Oncogene"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.47.30022","article-title":"Identification of the product of growth arrest-specific gene 6 as a common ligand for axl, sky, and mer receptor tyrosine kinases","volume":"271","author":"Nagata","year":"1996","journal-title":"J Biol Chem"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0392","article-title":"AXL-driven EMT state as a targetable conduit in cancer","volume":"77","author":"Antony","year":"2017","journal-title":"Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.4.2522","article-title":"Auto-oxidation and oligomerization of protein s on the apoptotic cell surface is required for mer tyrosine kinase-mediated phagocytosis of apoptotic cells","volume":"180","author":"Uehara","year":"2008","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.6.1952","article-title":"Transforming genes in chronic myelogenous leukemia","volume":"85","author":"Liu","year":"1988","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.6.1931.1931","article-title":"Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis","volume":"84","author":"Neubauer","year":"1994","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.11.10.5016","article-title":"Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase","volume":"11","author":"O\u2019Bryan","year":"1991","journal-title":"Mol Cell Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.428","article-title":"Giving AXL the axe: targeting AXL in human malignancy","volume":"116","author":"Gay","year":"2017","journal-title":"Br J Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1042\/CS20110411","article-title":"Axl-dependent signalling: a clinical update","volume":"122","author":"Korshunov","year":"2012","journal-title":"Clin Sci (Lond)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.13.8.4976","article-title":"The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein s, a negative coregulator in the blood coagulation cascade","volume":"13","author":"Manfioletti","year":"1993","journal-title":"Mol Cell Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90520-0","article-title":"The anticoagulation factor protein s and its relative, Gas6, are ligands for the tyro 3\/Axl family of receptor tyrosine kinases","volume":"80","author":"Stitt","year":"1995","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/373623a0","article-title":"Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6","volume":"373","author":"Varnum","year":"1995","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7600912","article-title":"Structural basis for Gas6-axl signalling","volume":"25","author":"Sasaki","year":"2006","journal-title":"EMBO J"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1201123","article-title":"Intracellular signaling of the Ufo\/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site","volume":"14","author":"Braunger","year":"1997","journal-title":"Oncogene"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1458","article-title":"Molecular pathways: AXL, a membrane receptor mediator of resistance to therapy","volume":"22","author":"Scaltriti","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.03752.x","article-title":"Gas6 is complexed to the soluble tyrosine kinase receptor axl in human blood","volume":"8","author":"Ekman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.12.7123","article-title":"GAS6 induces axl-mediated chemotaxis of vascular smooth muscle cells","volume":"273","author":"Fridell","year":"1998","journal-title":"J Biol Chem"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.37.23285","article-title":"GAS6 mediates adhesion of cells expressing the receptor tyrosine kinase axl","volume":"272","author":"McCloskey","year":"1997","journal-title":"J Biol Chem"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.19.12.8075","article-title":"Axl-gas6 interaction counteracts E1A-mediated cell growth suppression and proapoptotic activity","volume":"19","author":"Lee","year":"1999","journal-title":"Mol Cell Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(02)00016-X","article-title":"Macrophage regulation by tyro 3 family receptors","volume":"15","author":"Lemke","year":"2003","journal-title":"Curr Opin Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.07.034","article-title":"Comprehensive characterization of cancer driver genes and mutations","volume":"174","author":"Bailey","year":"2018","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1354","article-title":"AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer","volume":"20","author":"Dunne","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9231","article-title":"The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma","volume":"7","author":"Hsieh","year":"2016","journal-title":"Oncotarget"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e0154767","DOI":"10.1371\/journal.pone.0154767","article-title":"Axl expression stratifies patients with poor prognosis after hepatectomy for hepatocellular carcinoma","volume":"11","author":"Liu","year":"2016","journal-title":"PloS One"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/mc.20211","article-title":"Growth arrest-specific gene 6 and axl signaling enhances gastric cancer cell survival via akt pathway","volume":"46","author":"Sawabu","year":"2007","journal-title":"Mol Carcinog"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.7150\/jca.47318","article-title":"Co-Overexpression of AXL and c-ABL predicts a poor prognosis in esophageal adenocarcinoma and promotes cancer cell survival","volume":"11","author":"Hong","year":"2020","journal-title":"J Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1593\/neo.122044","article-title":"AXL mediates TRAIL resistance in esophageal adenocarcinoma","volume":"15","author":"Hong","year":"2013","journal-title":"Neoplasia"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27492","article-title":"Axl activates autocrine transforming growth factor-beta signaling in hepatocellular carcinoma","volume":"61","author":"Reichel","year":"2015","journal-title":"Hepatology"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17598","article-title":"Soluble axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis","volume":"8","author":"Dengler","year":"2017","journal-title":"Oncotarget"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.8.7.7923","article-title":"The axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target","volume":"8","author":"Koorstra","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3962","article-title":"AXL is an oncotarget in human colorectal cancer","volume":"6","author":"Martinelli","year":"2015","journal-title":"Oncotarget"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq1184","article-title":"NCBI GEO: archive for functional genomics data sets\u201310 years on","volume":"39","author":"Barrett","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3109\/0284186X.2014.975839","article-title":"Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature","volume":"54","author":"Bockelman","year":"2015","journal-title":"Acta Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.clim.2016.05.011","article-title":"Heightened cleavage of axl receptor tyrosine kinase by ADAM metalloproteases may contribute to disease pathogenesis in SLE","volume":"169","author":"Orme","year":"2016","journal-title":"Clin Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0933","article-title":"Reduced proteolytic shedding of receptor tyrosine kinases is a post-translational mechanism of kinase inhibitor resistance","volume":"6","author":"Miller","year":"2016","journal-title":"Cancer Discovery"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29394","article-title":"Multicenter analysis of soluble axl reveals diagnostic value for very early stage hepatocellular carcinoma","volume":"137","author":"Reichl","year":"2015","journal-title":"Int J Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"103797","DOI":"10.1016\/j.ebiom.2021.103797","article-title":"Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis","volume":"75","author":"Martinez-Bosch","year":"2022","journal-title":"EBioMedicine"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2015.02.006","article-title":"Sustained proliferation in cancer: mechanisms and novel therapeutic targets","author":"Feitelson","year":"2015","journal-title":"Semin Cancer Biol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.504","article-title":"AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma","volume":"30","author":"Xu","year":"2011","journal-title":"Oncogene"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i38.5369","article-title":"Axl glycosylation mediates tumor cell proliferation, invasion and lymphatic metastasis in murine hepatocellular carcinoma","volume":"18","author":"Li","year":"2012","journal-title":"World J Gastroenterol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0075","article-title":"S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab","volume":"12","author":"Burbridge","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3847","article-title":"The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer","volume":"14","author":"Graham","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.212","article-title":"Axl as a potential therapeutic target in cancer: role of axl in tumor growth, metastasis and angiogenesis","volume":"28","author":"Li","year":"2009","journal-title":"Oncogene"},{"key":"B64","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000147748","article-title":"An overview of epithelio-mesenchymal transformation","volume":"154","author":"Hay","year":"1995","journal-title":"Acta Anat (Basel)"},{"key":"B65","doi-asserted-by":"publisher","first-page":"110909","DOI":"10.1016\/j.biopha.2020.110909","article-title":"EMT, cancer stem cells and autophagy; the three main axes of metastasis","volume":"133","author":"Babaei","year":"2021","journal-title":"BioMed Pharmacother"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0909333107","article-title":"Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival","volume":"107","author":"Gjerdrum","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B67","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","article-title":"Emt: 2016","volume":"166","author":"Nieto","year":"2016","journal-title":"Cell"},{"key":"B68","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41591-020-01195-4","article-title":"Targeting metastatic cancer","volume":"27","author":"Ganesh","year":"2021","journal-title":"Nat Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0528","article-title":"Role of the receptor tyrosine kinase axl in hepatocellular carcinoma and its clinical relevance","volume":"15","author":"Niu","year":"2019","journal-title":"Future Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0373-6","article-title":"Integrated analysis of multiple receptor tyrosine kinases identifies axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma","volume":"120","author":"Pinato","year":"2019","journal-title":"Br J Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.650963","article-title":"AXL overexpression in tumor-derived endothelial cells promotes vessel metastasis in patients with hepatocellular carcinoma","volume":"11","author":"Chai","year":"2021","journal-title":"Front Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-2887-T","article-title":"Warfarin blocks Gas6-mediated axl activation required for pancreatic cancer epithelial plasticity and metastasis","volume":"75","author":"Kirane","year":"2015","journal-title":"Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-1973","article-title":"Small-molecule inhibition of axl targets tumor immune suppression and enhances chemotherapy in pancreatic cancer","volume":"78","author":"Ludwig","year":"2018","journal-title":"Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2474805","DOI":"10.1155\/2019\/2474805","article-title":"Ursolic acid inhibits epithelial-mesenchymal transition through the Axl\/NF-kappaB pathway in gastric cancer cells","volume":"2019","author":"Li","year":"2019","journal-title":"Evid Based Complement Alternat Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2018.08.005","article-title":"AXL mediates esophageal adenocarcinoma cell invasion through regulation of extracellular acidification and lysosome trafficking","volume":"20","author":"Maacha","year":"2018","journal-title":"Neoplasia"},{"key":"B76","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12032-021-01464-3","article-title":"Dual inhibition of TGFbeta and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype","volume":"38","author":"Ciardiello","year":"2021","journal-title":"Med Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i34.3834","article-title":"Drug resistance and new therapies in colorectal cancer","volume":"24","author":"Van der Jeught","year":"2018","journal-title":"World J Gastroenterol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01138","article-title":"Cabozantinib (XL184) and R428 (BGB324) inhibit the growth of esophageal squamous cell carcinoma (ESCC)","volume":"9","author":"Yang","year":"2019","journal-title":"Front Oncol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"835680","DOI":"10.1155\/2010\/835680","article-title":"Molecular mechanisms of resistance to tumour anti-angiogenic strategies","author":"Grepin","year":"2010","journal-title":"J Oncol 2010."},{"key":"B80","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/9780470319413.ch14","article-title":"Molecular control of vascular smooth muscle cell differentiation and phenotypic plasticity","volume":"283","author":"Owens","year":"2007","journal-title":"Novartis Found Symp"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01613-17","article-title":"Axl can serve as entry factor for lassa virus depending on the functional glycosylation of dystroglycan","volume":"92","author":"Fedeli","year":"2018","journal-title":"J Virol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2012.21","article-title":"Axl is essential for VEGF-a-dependent activation of PI3K\/Akt","volume":"31","author":"Ruan","year":"2012","journal-title":"EMBO J"},{"key":"B83","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jcmgh.2017.03.005","article-title":"Regulation of gastric carcinogenesis by inflammatory cytokines","volume":"4","author":"Bockerstett","year":"2017","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2010.223","article-title":"Immune parameters affecting the efficacy of chemotherapeutic regimens","volume":"8","author":"Zitvogel","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3390\/cancers8100097","article-title":"The role of TAM family receptors in immune cell function: implications for cancer therapy","volume":"8","author":"Paolino","year":"2016","journal-title":"Cancers (Basel)"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/ni1353","article-title":"Natural killer cell differentiation driven by Tyro3 receptor tyrosine kinases","volume":"7","author":"Caraux","year":"2006","journal-title":"Nat Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1126\/science.1061663","article-title":"Homeostatic regulation of the immune system by receptor tyrosine kinases of the tyro 3 family","volume":"293","author":"Lu","year":"2001","journal-title":"Science"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0007-1","article-title":"Targeting the tumour stroma to improve cancer therapy","volume":"15","author":"Valkenburg","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"a008748","DOI":"10.1101\/cshperspect.a008748","article-title":"Clearing the dead: apoptotic cell sensing, recognition, engulfment, and digestion","volume":"5","author":"Hochreiter-Hufford","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-2614","article-title":"Pan-TAM tyrosine kinase inhibitor BMS-777607 enhances anti-PD-1 mAb efficacy in a murine model of triple-negative breast cancer","volume":"79","author":"Kasikara","year":"2019","journal-title":"Cancer Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-16-0350","article-title":"Phosphatidylserine sensing by TAM receptors regulates AKT-dependent chemoresistance and PD-L1 expression","volume":"15","author":"Kasikara","year":"2017","journal-title":"Mol Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12943-019-1022-2","article-title":"Targeting Tyro3, axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment","volume":"18","author":"Myers","year":"2019","journal-title":"Mol Cancer"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.9.5635","article-title":"Macrophages and dendritic cells use different Axl\/Mertk\/Tyro3 receptors in clearance of apoptotic cells","volume":"178","author":"Seitz","year":"2007","journal-title":"J Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1302507110","article-title":"Paradoxical role of the proto-oncogene axl and mer receptor tyrosine kinases in colon cancer","volume":"110","author":"Bosurgi","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20051725","article-title":"Twist mediates suppression of inflammation by type I IFNs and axl","volume":"203","author":"Sharif","year":"2006","journal-title":"J Exp Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0909610","article-title":"TNF-alpha, IL-6, and IL-1 expression is inhibited by GAS6 in monocytes\/macrophages","volume":"87","author":"Alciato","year":"2010","journal-title":"J Leukoc Biol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"29673","DOI":"10.1038\/srep29673","article-title":"Liver X receptor and STAT1 cooperate downstream of Gas6\/Mer to induce anti-inflammatory arginase 2 expression in macrophages","volume":"6","author":"Kim","year":"2016","journal-title":"Sci Rep"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.etap.2016.05.029","article-title":"Exogenous Gas6 attenuates silica-induced inflammation on differentiated THP-1 macrophages","volume":"45","author":"Shen","year":"2016","journal-title":"Environ Toxicol Pharmacol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124184","article-title":"Sitravatinib potentiates immune checkpoint blockade in refractory cancer models","volume":"3","author":"Du","year":"2018","journal-title":"JCI Insight"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.gde.2008.01.004","article-title":"Acquired resistance to tyrosine kinase inhibitors during cancer therapy","volume":"18","author":"Engelman","year":"2008","journal-title":"Curr Opin Genet Dev"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-0803-9","article-title":"Tumor-associated macrophage-secreted 14-3-3zeta signals via AXL to promote pancreatic cancer chemoresistance","volume":"38","author":"D\u2019Errico","year":"2019","journal-title":"Oncogene"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.03.012","article-title":"Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET\/AXL dysregulation","volume":"155","author":"Park","year":"2021","journal-title":"Lung Cancer"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat Genet"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0116","article-title":"Targeting axl and mer kinases in cancer","volume":"10","author":"Verma","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.010","article-title":"AXL mediates resistance to PI3Kalpha inhibition by activating the EGFR\/PKC\/mTOR axis in head and neck and esophageal squamous cell carcinomas","volume":"27","author":"Elkabets","year":"2015","journal-title":"Cancer Cell"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14089","article-title":"Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells","volume":"110","author":"Yoshioka","year":"2019","journal-title":"Cancer Sci"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210173","article-title":"A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors","volume":"26","author":"Mahadevan","year":"2007","journal-title":"Oncogene"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22394","article-title":"MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.08.020","article-title":"Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer","volume":"163","author":"Fuh","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/cancers8110103","article-title":"The receptor tyrosine kinase AXL in cancer progression","volume":"8","author":"Rankin","year":"2016","journal-title":"Cancers (Basel)"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-1366","article-title":"S100A10 is a critical mediator of GAS6\/AXL-induced angiogenesis in renal cell carcinoma","volume":"79","author":"Xiao","year":"2019","journal-title":"Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-21-0302","article-title":"GAS6\/AXL inhibition enhances ovarian cancer sensitivity to chemotherapy and PARP inhibition through increased DNA damage and enhanced replication stress","volume":"20","author":"Mullen","year":"2022","journal-title":"Mol Cancer Res"},{"key":"B113","doi-asserted-by":"publisher","first-page":"9953","DOI":"10.3390\/ijms22189953","article-title":"Therapeutic targeting of the Gas6\/Axl signaling pathway in cancer","volume":"22","author":"Tanaka","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0282","article-title":"CT-707, a novel FAK inhibitor, synergizes with cabozantinib to suppress hepatocellular carcinoma by blocking cabozantinib-induced FAK activation","volume":"15","author":"Wang","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12524","article-title":"Cabozantinib reverses multidrug resistance of human hepatoma HepG2\/adr cells by modulating the function of p-glycoprotein","volume":"35","author":"Xiang","year":"2015","journal-title":"Liver Int"},{"key":"B116","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"B117","doi-asserted-by":"publisher","first-page":"9953","DOI":"10.7554\/eLife.03385","article-title":"Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities","volume":"3","author":"Lew","year":"2014","journal-title":"Elife"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220101","article-title":"Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance","volume":"14","author":"Dolan","year":"2019","journal-title":"PloS One"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6547","article-title":"Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma","volume":"7","author":"Patwardhan","year":"2016","journal-title":"Oncotarget"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.7150\/thno.27667","article-title":"BPI-9016M, a c-met inhibitor, suppresses tumor cell growth, migration and invasion of lung adenocarcinoma via miR203-DKK1","volume":"8","author":"Zhang","year":"2018","journal-title":"Theranostics"},{"key":"B121","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13045-019-0834-2","article-title":"First-in-human phase I study of BPI-9016M, a dual MET\/Axl inhibitor, in patients with non-small cell lung cancer","volume":"13","author":"Hu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4443","article-title":"An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms","volume":"67","author":"Zou","year":"2007","journal-title":"Cancer Res"},{"key":"B123","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1080\/15384047.2017.1364323","article-title":"Preclinical rationale for combination of crizotinib with mitomycin c for the treatment of advanced colorectal cancer","volume":"18","author":"Lev","year":"2017","journal-title":"Cancer Biol Ther"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-019-2118-z","article-title":"CAR T cell therapy for hematological malignancies","volume":"39","author":"Yang","year":"2019","journal-title":"Curr Med Sci"},{"key":"B126","doi-asserted-by":"publisher","first-page":"107419","DOI":"10.1016\/j.pharmthera.2019.107419","article-title":"Clinical investigation of CAR T cells for solid tumors: lessons learned and future directions","volume":"205","author":"Bagley","year":"2020","journal-title":"Pharmacol Ther"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0385","article-title":"Emerging CAR-T cell therapy for the treatment of triple-negative breast cancer","volume":"19","author":"Dees","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B128","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cellimm.2018.05.004","article-title":"A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers","volume":"331","author":"Wei","year":"2018","journal-title":"Cell Immunol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.02.054","article-title":"Burden of pancreatic cancer: from epidemiology to practice","volume":"19","author":"Khalaf","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pathmechdis.3.121806.154305","article-title":"Pancreatic cancer","volume":"3","author":"Maitra","year":"2008","journal-title":"Annu Rev Pathol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1079041\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T12:45:49Z","timestamp":1688474749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1079041\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,4]]},"references-count":130,"alternative-id":["10.3389\/fonc.2023.1079041"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1079041","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,4]]},"article-number":"1079041"}}